ABSTRACT Vein (Vn), a ligand for the Drosophila epidermal growth factor receptor (Egfr), has a complex structure including a PEST, Ig, and EGF domain. We analyzed the structure-function relationships of Vn by assaying deletion mutants. The results show that each conserved domain influences Vn activity. A PEST deletion increases Vn potency and genetic evidence suggests that Vn is regulated by proteasomal degradation. The Ig deletion causes toxic effects not seen following expression of native Vn, but the Ig domain is not required for Vn localization or for the activation of Egfr signaling in wing vein patterning. Remarkably, when the EGF domain is deleted, Vn functions as a dominant negative ligand, implying that Vn normally physically interacts with another factor to promote its activity. We identified additional highly conserved sequences and found several regions that affect Vn potency and one that may mediate the effect of dominant negative Vn molecules. Together the results show that the activity of Vn is controlled both positively and negatively, demonstrating the existence of additional levels at which Egfr signaling can be regulated.
domestica (Howes et al. 1998) , understanding how Aos tionships of Vn will give insight into possible domains through which these factors may act. functions is of considerable interest and may lead to the Structurally, Vn resembles the vertebrate neuregulins development of vertebrate Egfr inhibitors that could have because it possesses an Ig domain in addition to the therapeutic use in human disease.
EGF motif. The neuregulins exist in multiple different Howes et al. (1998) investigated structure-function isoforms and those containing an Ig domain are essenrelationships of the ligands Spi and Aos by creating a tial for viability (Meyer and Birchmeier 1995; Kramer set of chimeras between the two proteins. They found et al. 1996) . Here we sought to understand the roles of that swapping the EGF domains of these proteins elimithe EGF, Ig, and other key domains in Vn. The results nated their function; neither the Spi EGF domain in suggest Vn interacts with multiple factors that control Aos nor the Aos EGF domain in Spi had activating or its activity both positively and negatively, thus providing inhibiting properties. In contrast, a chimeric molecule additional levels at which Egfr signaling can be regulated. in which the Aos EGF domain was swapped with that of Vn (Vn::Aos-EGF) resulted in the conversion of the activator Vn into an inhibitor (Schnepp et al. 1998) .
MATERIALS AND METHODS
The simplest interpretation of this result is that the Aos EGF motif is sufficient for receptor inhibition. However,
Sequencing of vein EMS alleles:
The vein alleles (allele here we report surprisingly that a Vn molecule completely name/synonym) sequenced were: L6, WA178, ddd3/RG436, lacking an EGF domain is also an inhibitor. Thus both VW100, and ddd-13/WB240. Mutant larvae were either homozymolecules function as dominant negative ligands, suggous for a given allele or trans-heterozygous with Df(3L) vn-␥3. gesting that the Aos EGF domain may not play a significant reactions, one using primers pBS T3 and DEGF-R and the Unlike the TGF-␣ agonists, Vn is made as a secreted other using pBS T7 and DEGF-F. The products, corresponding molecule and is not dependent on proteolytic activato residues 1-564 and 599-622, respectively, were cut with XmaI, ligated, and cloned into the EcoRI site of pBS.
tion. vn is expressed in a spatially restricted pattern Vn:⌬Ig: pBS-Vn1 was used as a template for PCR with primers Simcox et al. 1996) ; however, it pBS T7 and DIg-F. The PCR product, corresponding to resiis clear that transcription of vn per se does not always dues 522-622, was cut with BglII/NotI and used to replace the lead to an active ligand. Ectopic expression of vn in the corresponding fragment in pBS-Vn1.
early wing disc, where it acts as the key activator of Egfr
Vn:⌬MR : The orientation of the Vn1 cDNA in pBS was reversed and the resulting construct (named pBS-Vn1 R ) was signaling, does not mimic the transformations induced used as a template for PCR with primers T7 and MR3-R. The by ectopic expression of a consitutively active receptor PCR product, corresponding to residues 1-92, was cut with (Wang et al. 2000; Zecca and Struhl 2002 Vn activity. Understanding the structure-function rela- an internal SphI fragment corresponding to residues 177-395, copy. Immunostaining of embryos was performed using standard procedures (Patel 1994) . A rat polyclonal to Vn (kindly and religated.
Vn:⌬MR : pBS-Vn1 was used as a template for PCR with provided by T. Volk; Yarnitzky et al. 1997) was diluted 1:200 and Cy3-conjugated goat-anti-rat secondary ( Jackson) was dithe primers pBS T7 and MR2-F. The PCR product, corresponding to residues 477-621, was cut with SacII and used to replace luted 1:500. Embryos were mounted in Vectashield (Vector Laboratories, Burlingame, CA) and analyzed with a Bio-Rad the corresponding fragment in pBS-Vn1.
Vn:⌬PEST: pBS-Vn1 was used as a template for PCR, using (Richmond, CA) MRC 1024 confocal laser microscope. Bromodeoxyuridine labeling: Larvae were dissected in primers pBS T3 and DP-R. The product, corresponding to residues 1-41, was cut with AflII/XhoI and used to replace the Schneider cell medium and inverted anterior ends were incubated in Schneider cell medium containing 50 g/ml bromocorresponding fragment in pBS-Vn1.
Constructs were excised from pBS and inserted into the deoxyuridine (BrdU; Roche Molecular Biochemicals, Indianapolis) for 30 min to label proliferating cells. BrdU detection transformation vector pUAST. Transgenic stocks were generated by standard techniques and multiple transgenic lines for was as previously described (Hartenstein and Posakony 1989) with mouse anti-BrdU (Becton-Dickinson) used 1:20 each construct were examined (see below). Primer sequences are listed in supplemental material at http:/ /www.genetics. and a goat-anti-mouse HRP-conjugated secondary ( Jackson) used 1:300. Tissues were mounted in Aquapolymount for analorg/supplemental/. Drosophila stocks and cultures: All crosses were performed ysis by brightfield microscopy. at 25Њ, unless otherwise noted. All Gal4 lines (71B, 69B, bs-1348, en, Kr, and ptc) and the DTS5 and DTS7 proteasome subunit alleles were obtained from the Bloomington Stock RESULTS Center. To account for differences in expression due to position effects, we analyzed at least five independent transgenic Temperature-sensitive mutations map to the Ig and lines for each construct, except for the Aos/Spi chimeras, for EGF domain: Nine EMS-induced vn alleles were sequenced which a minimum of two lines were examined (Table 1 ). In ( Figure 1A) product would terminate at a premature STOP codon ning of the Ig domain that is affected in the conditional ddd-13 mutant is conserved between all four proteins. in intron 2. The two missense mutants, ddd-13 and ddd-11, each contain a single amino acid change, in the Ig
There is also a high degree of similarity in the region just N terminal to the Ig domain, which we term the domain and the EGF domain, respectively. Both ddd-13 and ddd-11 are temperature-sensitive mutations, sugmosquito-conserved region (MCR; Figure 1B ). The N-terminal portion of the gene has lower conservation (data gesting that these two regions are key determinants of Vn structure and function. This has been confirmed by not shown). As expected for a region with strong evolutionary conservation, deletions removing parts of the examining deletion mutants as described below.
Comparison with Anopheles gambiae and other Drosoph-MCR impair the function of Vn (see below).
Vn::Aos/Spi-EGF chimeras function as inhibitors:
A ila species reveals additional highly conserved regions: To determine if there are conserved regions in addition to chimeric molecule composed of the Aos EGF domain inserted into the Vn backbone (Vn::Aos-EGF) inhibited the Ig and EGF domains, we compared the Vn sequences from other Drosophilids and a mosquito. The genomes Egfr signaling (Schnepp et al. 1998 ; Figure 2B ). In an attempt to define the region within the Aos EGF motif of A. gambiae and Drosophila pseudoobscura were recently sequenced (Holt et al. 2002; Human Genome Sequencing conferring this property, we created a set of chimeric Vn molecules with EGF motifs corresponding to all possible Center, Baylor College of Medicine, http:/ /hgsc.bcm.tmc. edu/projects/drosophila/). The A. gambiae vn cDNA combinations of the A, B, and C loops from the Spi and Aos EGF motifs (Vn::Aos/Spi-EGF chimeras, Figure 2C ). sequence was further confirmed by reverse transcriptase (RT)-PCR (data not shown). We also cloned and seWe chose to test chimeras between the Spi and Aos EGF motifs rather than between the Vn and Aos EGF motifs quenced the D. virilis vn gene using degenerate RT-PCR and RACE (see materials and methods).
because it has been shown that Spi is a stronger activator than Vn (Schnepp et al. 1998; Golembo et al. 1999) , The structure of the vn gene is conserved between the Drosophilids and A. gambiae, with an exon coding and thus the difference in activity of the chimeric EGF motifs would be more apparent. for most of the protein followed by one large intron and several small exons that encode the Ig and EGF
We tested the activity of each chimera using the Gal4-UAS system (Brand and Perrimon 1993). UAS-transdomains (data not shown). Interestingly, the EGF domain in each vn gene is divided by an intron located genes encoding the chimeras were misexpressed in the wing and their ability to produce vein loss, characteristic between the fourth and fifth cysteines. Stein and Staros (2000) report that genes for vertebrate ErbB ligands of Egfr inhibitors, or ectopic veins, characteristic of Egfr activators, was assessed. Surprisingly, every one of the contain a splice site in the same position. The placement of this intron appears to be unique to ErbB ligands and chimeras functioned as an inhibitor (Table 1) . Each EGF motif chimera had approximately the same activity is not generally seen in other EGF-domain-containing proteins (Stein and Staros 2000) , suggesting that the (one shown in Figure 2D ), which was also similar to that of Vn::Aos-EGF ( Figure 2B ), except A3S4A (Aos A insect and vertebrate genes share a common ancestry.
The overall identity of the D. melanogaster Vn protein and C loops with the Spi B loop, Table 1 ) that had weaker activity. We suspect that this chimera acts as a weak inhibiis 70% with D. pseudoobscura, 58% with D. virilis, and 26% with A. gambiae. The sequences of the Ig (Figure tor due to a nonspecific defect rather than to an effect of the Spi B loop because the two other chimeras that 1C) and EGF ( Figure 1D ) domains from these species are strongly conserved. The proline triplet at the begininclude this region (A3S and S4A) are potent inhibitors. Vn and DN-Vn transgenes were coexpressed using 69B-GAL4 and the resulting wing phenotypes were analyzed. Figure 4C ).
Vn:⌬EGF functions as an Egfr inhibitor: Finding that
However, the Ig domain clearly has a function because all Vn::Aos/Spi-EGF chimeras tested functioned as inthe effect of Vn:⌬Ig differed from wild-type Vn when mishibitors suggested that the sequence of the Aos EGF expressed earlier in development. Misexpression of Vn: motif was not critically important for mediating the in⌬Ig resulted in complete lethality with 71B-GAL4, whereas hibitory effect of Vn::Aos-EGF and that the mechanism misexpression of wild-type Vn only slightly affected viabilof inhibition was distinct from that of native Aos. One ity. Expression of wild-type Vn with 69B-GAL4 Vn induced explanation could be that all chimeras possess nonfuncpartial lethality but this occurred at the pupal stage, tional EGF domains that cannot bind Egfr but interfere whereas misexpression of Vn:⌬Ig was embryonic lethal with signaling in a dominant negative fashion by affect-(data not shown). We found one transgenic line of ing a pathway component other than the receptor. ThereVn:⌬Ig that produced adults with 69B-GAL4, presumfore we tested whether an EGF domain was required for ably because the insertion site of the transgene supports inhibition by creating a form of Vn lacking the EGF doonly relatively low expression levels. These exhibited a main (Vn:⌬EGF). If the inhibition occurred through a moderate extra-vein phenotype ( Figure 4F ) similar to dominant negative mechanism not involving receptor that caused by ectopic expression of native Vn, but this binding, then Vn:⌬EGF would also be expected to funcVn:⌬Ig line also consistently produced serrated wing tion as an inhibitor. Indeed this was found to be the case.
margins, which were only rarely seen following Vn misMisexpression of Vn:⌬EGF with 69B-GAL4 produced expression, demonstrating an abnormal function for a vein-loss phenotype in the wing similar, although the Ig deletion mutant. somewhat milder, to that produced by misexpression Finally, misexpression of Vn:⌬Ig with T80-GAL4 reof Vn::Aos-EGF and the Vn::Aos/Spi-EGF inhibitors sulted in bloated larvae ( Figure 4D ). The brains and ( Figure 3A ). These phenotypes also closely resemble imaginal discs in these larvae were smaller than those that of a hypomorphic mutation of vn (Puro 1982;  of wild type and showed reduced levels of BrdU incorpo- Figure 3B ), further suggesting that the transgenes are ration ( Figure 4E ), indicating a defect in cell proliferafunctioning as inhibitors through a dominant negative tion in these tissues. Misexpression of native Vn caused mechanism, possibly by interfering with the activity of mild larval bloating but did not result in either of these endogenous Vn. In this model, Vn activity would be disc or brain phenotypes. Together these data show that compromised because the inhibitors compete with Vn for the Ig domain is not required for Vn to function as an a factor required to promote ligand-receptor interaction.
activator, but nevertheless indicate a role for the Ig domain One prediction of this model is that in addition to in modulating Vn activity because expression of Vn:⌬Ig being able to prevent endogenous Vn from activating is toxic early in development. Egfr, Vn:⌬EGF and Vn::Aos-EGF (hereafter referred to
The dominant negative effect of DN-Vn is not medicollectively as DN-Vn ligands) would also be able to ated by the Ig domain: The Ig domain is a known protein-protein interaction domain and therefore a candiinhibit misexpressed, native Vn. To test this, wild-type date region for mediating the effect of the DN-Vn proteins (Rechsteiner and Rogers 1996) . Thus, if the PEST domain of Vn is functional, its removal would be ligands such that the phenotypes caused by these ligands may result from sequestering a positive factor normally expected to generate a more stable protein. Misexpression of Vn:⌬PEST with 69B-GAL4 and 71B-GAL4 caused bound by the Ig domain of Vn. To test this, we generated flies expressing DN-Vn constructs in which the Ig lethality whereas misexpression with 1348-GAL4 resulted in a strong extra-vein phenotype ( Figure 5B ). This phenodomain was deleted (Vn::Aos-EGF-⌬Ig and Vn:⌬EGF-⌬Ig). These proteins were robustly expressed and localtype was more severe than that resulting from misexpression of wild-type Vn ( Figure 5A ), indicating that Vn:⌬PEST ized in the ECM (not shown) but had no detectable effect on Egfr signaling. This suggests that either the has enhanced signaling capacity, possibly through an increase in protein stability. Misexpression of Vn:⌬PEST Ig domain is required for the function of the DN-Vn inhibitors or the proteins are inactive due to a nonsperesulted in a high level of Vn expression in embryos and the protein appeared to be more widely distributed cific effect. To distinguish between these possibilities, we tested for genetic interactions between DN-Vn and and not limited primarily to the surface of cells ( Figure  5C ). This distribution could be a result of Vn persisting Vn:⌬Ig. If the DN-Vn ligands were functioning through a mechanism involving the Ig domain, then DN-Vn in the cells. PEST domains are involved in targeting proteins to would not be expected to alter the phenotype of Vn:⌬Ig, as this molecule would necessarily function indepenthe 26S proteasome. In Drosophila, two mutants, DTS5 and DTS7, affect the ␤6 and ␤2 proteasome subunit dently of the Ig domain.
We analyzed the phenotypes resulting from coexpresgenes, respectively (Mykles 1999) . DTS5 and DTS7 heterozygous flies develop normally at the permissive temsion of Vn:⌬Ig and DN-Vn (with 69B-GAL4). We found that the wing phenotypes caused by expression of the perature (25Њ), but die in the pupal stage when grown at the restrictive temperature (29Њ). Shifting to the reweaker Vn:⌬Ig line were rescued by coexpression of DN-Vn ( Figure 4G ). (This phenotype was also rescued strictive temperature for 48 hr during the third larval instar allows the flies to survive to adulthood and these by coexpression with UAS-Aos, which demonstrates that Vn:⌬Ig is having its effects through the Egfr pathway exhibit a mild extra-vein phenotype ( Figure 5 , D and E; both alleles have vein spurs around L5, not shown). Figure 4 , H and I.) Furthermore, while expression of most Vn:⌬Ig lines alone resulted in embryonic lethality
The UAS-Vn 1.1 line also has a mild constitutive extra-vein phenotype caused by leaky expression of the transgene (see above), we found that coexpression of DN-Vn rescued this lethality and produced viable adult progeny ( Figure 5F ). In combination with the DTS5 and DTS7 mutations and following a shift to the restrictive temperthat exhibited a mild extra-vein phenotype (not shown). Thus DN-Vn ligands are effective suppressors of Vn ature, this extra-vein phenotype is dramatically enhanced ( Figure 5 , G and H), suggesting that impairing molecules lacking an Ig domain, suggesting that some other region mediates the dominant negative effect. We proteasome function enhances Vn activity, possibly by reducing Vn degradation. suggest that this region is part of a highly conserved sequence (MCR) in the middle portion of Vn (see Amino acids 177-476 of Vn are required for full activity whereas amino acids 93-177 negatively regulate Vn below).
Vn:⌬PEST is a stronger agonist than native Vn: PEST activity: The Vn middle region (amino acids 93-476) lacks sequences with homology to known functional domains serve as signals for proteolytic degradation of is indeed required for Vn function and that some parts promote activity while another negatively regulates Vn activity.
Vn:⌬MR , which removes amino acids 93-213, functioned as a superstrong activator. Misexpression of Vn:⌬MR 93-213 with 69B-GAL4 and 71B-GAL4 caused embryonic and early pupal lethality, respectively. One line of Vn:⌬MR 93-213 appeared to be weaker than the others tested (presumably due to a position effect of the transgene insertion site). In this line, expression with 71B-GAL4 primarily caused lethality in late pupal/pharate adult stage but a few escapers survived that exhibited a strong extra-vein phenotype ( Figure 6C ). With expression induced by 1348-GAL4, most of the Vn:⌬MR lines produced a strong extra-vein phenotype and wing blisters ( Figure 6B ). These phenotypes are much stronger than those seen following misexpression of native Vn (Figures 4A and 6A) . In contrast, the mutants Vn:⌬MR and Vn:⌬MR , which remove amino acid residues 177-395 and 395-476, respectively, both functioned as weak activators when compared to native Vn, producing mild extra-vein phenotypes with a strong driver (69B-GAL4; Figure 6 , E and G). Together these results suggest that amino acid residues 93-213 of the "middle region" negatively regulate Vn activity whereas the remainder of the middle region is required for full Vn activity.
Amino acids 213-395 may mediate the dominant negative effect of DN-Vn ligands:
The DN-Vn ligands are presumed to function by competing with Vn for binding to a factor that promotes Vn/Egfr interaction. The region responsible for binding is therefore expected to Figure 3C ) and an extra-vein phenotype (F).
pression alone) and that the extra-vein phenotype of overexpression of Vn:⌬MR 395-476 ( Figure 6H ). Expression of Vn:⌬MR 395-476 alone resulted in deltas at the distal tips of L3 and L4 as well as a thickening of the distal domains, although stretches of the region are highly conserved with the mosquito (Figure 1B) . Deletion muportion of L2. Coexpression of DN-Vn eliminated these extra veins. tants spanning the middle region show that this region Mechanisms that govern production and presentation of an active ligand form the most fundamental quences between residues 213 and 395 in mediating the effect of the DN-Vn ligands and as the region in native levels of signaling control, presaging all other events in the pathway. Ligand activity can be controlled by both Vn that is required for binding a factor that promotes Vn/Egfr interaction. This falls within a region we found to transcriptional and/or post-translational regulation. Transcriptional regulation is important for vn, which, be highly conserved with the mosquito (MCR, Figure 1B) .
Deletion mutants with enhanced activity in the wing unlike the other zygotically active ligands spi and keren, is expressed in a highly localized and dynamic pattern do not influence embryonic cell fate: We found that each of the deletion mutants could at least partially (Rutledge et al. 1992; Schnepp et al. 1996; Yarnitzky et al. 1997; Golembo et al. 1999 ; rescue the wing disc phenotype of vn mutants (see supplemental Figure 2 at http://www.genetics.org/supple Wessells et al. 1999; Reich and Shilo 2002) . Vn is made as a soluble protein and thus does not require mental/). However, the observation that several of the Vn deletion mutants tested (Vn:⌬Ig, Vn:⌬PEST, and processing like the membrane spanning TGF-␣ ligands. However, its sequence predicts that Vn is a complex Vn:⌬MR ) differed from wild-type Vn in that they caused embryonic lethality suggested the possibility that molecule and here we have shown that the activity of Vn is indeed regulated through multiple functional dothese mutations were transforming Vn into a stronger agonist, more similar to Spi. Spi is more potent than mains that mediate both negative and positive effects on Vn activity. The results reveal additional levels of Vn when misexpressed in embryos and results in an expansion of ventral cell fates, which can be monitored complexity through which Egfr signaling is controlled and we discuss the potential conservation of these mechby examining the expression of orthodenticle (otd; Figure  7 , A-C; Wieschaus et al. 1992; Schweitzer et al. 1995b;  anisms. Deletion of the Vn EGF domain creates an inhibitor: Golembo et al. 1996a; Schnepp et al. 1998) . Misexpression of Vn:⌬Ig, Vn:⌬PEST, or Vn:⌬MR with KrRemarkably, when the EGF domain is deleted, Vn becomes an inhibitor. The activity of this mutant molecule GAL4 caused no expansion of otd expression (Figure 7, . This indicates that although two of these mutant is similar to that of a chimeric ligand, Vn::Aos-EGF (Schnepp et al. 1998) , that includes the EGF domain forms, Vn:⌬PEST and Vn:⌬MR , have enhanced capacity to induce ectopic veins and that all three cause from Aos, the natural Egfr antagonist. We had previously ascribed the inhibitory function of Vn::Aos-EGF to poslethality when expressed in the embryo, they do not (F, arrows) , suggesting that the latter region, which includes part of the MCR, is important for mediating the effect of DN-Vn. session of the Aos sequence but in light of the findings the possibility that a Vn dimer is part of the receptorligand complex because the two ligands are expected described here, it is likely that both Vn::Aos-EGF and Vn:⌬EGF function by a dominant negative mechanism.
to be ‫08-07ف‬ Å apart on opposite sides of the complex (Garrett et al. 2002; Ogiso et al. 2002) . However, this This also allows us to reconcile the difference in the activities of Vn::Aos-EGF and Spi::Aos-EGF chimeras does not rule out the possibility that Vn-Vn interactions have a role in subsequent multimerization of receptor (Howes et al. 1998; Schnepp et al. 1998) ; both share the Aos EGF domain, but only the Vn::Aos-EGF chimera dimers to form, for example, tetramers. In an alternative model, Vn/Egfr activation could depend on an interacis able to function as an inhibitor of Egfr signaling through a dominant negative mechanism involving a tion between Vn and another factor. In this case, overexpression of DN-Vn would compete for binding with this critical domain found only in the Vn "backbone."
Several possible models could explain how these DN-Vn factor and abrogate Vn-mediated receptor activation. Both models predict that there must be a region in mutants are able to inhibit Egfr signaling. In the simplest model, Vn/Egfr signaling could involve dimerization Vn that mediates the effect of the inhibitors by competing for binding to this factor. The normal role for this of Vn. A dimer formed between Vn and DN-Vn would likely be inactive. Expression of DN-Vn would thus reregion is therefore to potentiate Vn function and hence deletion of the region should lower Vn activity. Furtherduce the number of active Vn-Vn dimers and result in inhibition of Vn/Egfr signaling. However, the recent more, the model predicts that a molecule lacking the key region would not be influenced by the DN-Vn listructure of Egfr in complex with its ligands excludes gands. In our analysis of Vn deletion mutants we found destruction and structure-function analysis suggests that Vn may be regulated by degradation. Deletion of two two adjacent regions and MR ) that reduced Vn function in an ectopic expression assay. While regions in the N-terminal part of Vn produced mutant proteins with increased ability to activate Egfr as judged both deletions remove blocks of conserved sequences (MCR), only Vn:⌬MR 395-476 was able to be suppressed by by their ability to produce ectopic veins. One of these regions (amino acids 58-96) is strongly predicted to con-DN-Vn. This suggests that residues 213-395 are important for mediating the dominant negative effect. It will tain a PEST sequence (Figure 1 ) by the PestFind algorithm (Rechsteiner and Rogers 1996; http:/ /www.at.embnet. be important to map the required region in more detail to determine if the MCR performs this role, but our org/embnet/tools/bio/PESTFIND). Our observation that the removal of the PEST domain data indicate that the C-terminal portion of the MCR (which is relatively less conserved) is not required.
of Vn results in a more potent activator suggests that Vn is subject to regulation by protein degradation. This One question that arises from this work is whether an inhibitory vertebrate ligand can be created. van de would be a novel mechanism for regulation of an EGF ligand. In support of this idea we found a genetic interPoll et al. (1997) and Lohmeyer et al. (1997) generated EGF molecules with extended B loops in attempts to action between a vn transgene and mutants for proteasome subunits. Analyzing this connection further not mimic Argos function. None of these factors had inhibitory properties. While we believe the inhibitory nature only will be important for understanding Vn regulation, but also may have broader implications, as PEST doof Vn::Aos-EGF is primarily mediated through a dominant negative mechanism independent of the Aos semains have been reported in two other EGF ligands, Gurken and Lin-3 (Hill and Sternberg 1992; Neumanquence, we did note that the Vn::Aos-EGF chimera was a more potent inhibitor than Vn:⌬EGF because stronger Silberberg and Schüpbach 1993), and can also be detected in the neuregulins (S.-H. Wang and A. Simcox, induction of the transgene (elevating the rearing temperature to increase the activity of Gal4 and hence UASunpublished observations). Therefore, any such degradation mechanism may be conserved and involve multitransgene expression) was required to produce an equivalent phenotype. This suggests that some intrinsic ple ligands. Different roles for the Ig domain in Vn and the verteproperty of the Aos EGF domain also has an effect. But basing the design of an inhibitor on the Aos EGF region brate neuregulins: Of the four vertebrate neuregulin (NRG) genes, both NRG-1 and NRG-2 are alternatively is unlikely to be a successful approach, given the results with vertebrate ligands and the lack of activity of Spi::Aosspliced to produce isoforms that possess an Ig domain (Falls 2003 clear. Certain residues in the EGF domain are character-
